What Is Treatment-Resistant Depression? A Complete Guide for Pocatello Patients

By Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho

You've taken the pills. You gave them the full eight weeks. Maybe you've been through two different medications, or three, or more. Each time, you and your provider waited with cautious optimism, and each time, the depression either didn't budge or came back. You're starting to wonder whether depression is simply something you have to live with forever.

It isn't. But you do have a condition with a specific name, a specific biology, and a specific set of treatment options that goes well beyond what most primary care providers are equipped to offer.

That condition is treatment-resistant depression, and it is far more common — and far more treatable — than most patients in Pocatello and Southeast Idaho realize.

Treatment-resistant depression (TRD) is generally defined as major depressive disorder (MDD) that has failed to respond adequately to at least two antidepressant medications of different classes, each tried at an adequate dose for an adequate duration — typically 6 to 8 weeks at a therapeutic dose.

This definition has important nuances:

• "Adequate response" typically means a reduction of at least 50% in symptom severity on a validated scale such as the PHQ-9 or Hamilton Depression Rating Scale (HDRS). Less than that is considered a partial response; no meaningful change is a non-response.
• "Adequate dose" matters. A patient who took a low-dose SSRI for three weeks and stopped due to side effects has not completed an adequate trial.
• "Different classes" is significant. Trying two SSRIs is not the same as trying an SSRI and then an SNRI or a norepinephrine-dopamine reuptake inhibitor (NDRI).

Some researchers and clinicians use a more refined staging framework — the Thase-Rush Staging Model and the Maudsley Staging Method — that classifies the severity of treatment resistance on a spectrum based on the number and nature of failed trials.

More common than most people — and many providers — appreciate.

Major depressive disorder affects approximately 21 million American adults annually, making it one of the leading causes of disability worldwide. Of those treated with antidepressants, large-scale studies including the landmark STAR*D trial found that approximately 30–40% of patients do not achieve remission even after multiple adequate antidepressant trials.

Applying that proportion to Pocatello, Bannock County, and the surrounding Southeast Idaho region, the number of local residents living with inadequately treated depression is significant — and largely invisible, because TRD patients often disengage from a healthcare system that hasn't been able to help them.

Key Reference: Rush AJ, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917.

This is the question that defines the field — and increasingly, the answer is: because depression is not one disease.

The DSM-5 diagnostic criteria for major depressive disorder describe a syndrome — a cluster of symptoms — not a specific biological mechanism. Two patients who both meet criteria for MDD may have entirely different underlying neurobiology. This is why a treatment that works brilliantly for one patient does nothing for another.

Standard antidepressants — SSRIs, SNRIs, TCAs, MAOIs — work primarily by modulating monoamine neurotransmitters: serotonin, norepinephrine, and dopamine. This approach helps many patients. But it has inherent limitations:

• It doesn't address the glutamate system, which plays a central role in neuroplasticity and increasingly appears critical in TRD
• It doesn't address the HPA axis and chronic stress-driven cortisol dysregulation
• It doesn't address neuroinflammation, which is now recognized as a major driver of at least a subtype of depression

Research is increasingly identifying biological subtypes that explain non-response:

• Inflammatory depression: Elevated inflammatory cytokines (IL-6, TNF-α, CRP) are found in a significant subset of depressed patients and predict poor antidepressant response.
• HPA axis dysregulation: Hypercortisolemia — chronically elevated cortisol — damages hippocampal neurons, impairs neuroplasticity, and directly perpetuates depression in a self-reinforcing loop.
• Glutamate dysregulation: The NMDA receptor and glutamate system appear to be abnormally activated in TRD, which is why ketamine — an NMDA antagonist — produces rapid antidepressant effects in patients for whom serotonergic agents have failed.
• Thyroid and hormonal contributors: Thyroid dysfunction, estrogen dysregulation, and testosterone deficiency can each produce or perpetuate depression that does not respond to antidepressants because the root cause isn't being addressed.

Key Reference: Krishnan V, Nestler EJ. (2008). The molecular neurobiology of depression. Nature, 455(7215), 894–902.

TRD is not a benign condition to leave unaddressed. It is associated with:

• Higher rates of suicidal ideation and attempts than antidepressant-responsive depression
• Greater functional impairment — higher rates of disability, unemployment, and social isolation
• Worse medical outcomes — TRD is independently associated with cardiovascular disease, metabolic syndrome, and dementia risk
• Higher healthcare utilization and costs, including emergency department visits and hospitalizations
• Significant relationship and family strain

When standard antidepressants have failed, the treatment approach shifts. Evidence-based options for TRD include:

Adding a second medication to potentiate or enhance antidepressant response. Options with strong evidence include:

• Lithium augmentation: One of the oldest and best-supported augmentation strategies
• Atypical antipsychotics: Aripiprazole, quetiapine, and olanzapine are FDA-approved for adjunctive depression treatment
• Thyroid hormone (T3): Has demonstrated augmentation efficacy in multiple trials
• Buspirone: Used as an augmenter, particularly in SSRI partial responders

IV ketamine therapy produces rapid (often within hours) antidepressant effects via NMDA receptor antagonism and promotion of neuroplasticity. Multiple randomized controlled trials support its efficacy in TRD.

Intranasal esketamine (Spravato): The first FDA-approved treatment specifically indicated for TRD (2019). Administered in a certified healthcare setting.

Non-invasive neurostimulation delivering focused magnetic pulses to the dorsolateral prefrontal cortex. FDA-cleared for MDD and TRD. Response rates of 50–60% in TRD populations in clinical practice.

The most effective treatment for severe TRD, with remission rates of 60–80% in carefully selected patients. Modern ECT is safe and performed under general anesthesia.

Identifying and treating underlying physiological drivers: thyroid dysfunction, inflammatory contributors, nutritional deficiencies, hormonal imbalances, and gut-brain axis disruption.

Access to TRD-specialized care is one of the persistent challenges of living in a rural or semi-rural region. Pocatello-area patients often face significant barriers: provider shortages, long waits for specialist evaluation, limited local access to ketamine therapy or TMS, and primary care providers who may not be current on TRD treatment algorithms.

At Roth Family Medicine and Mental Health, we specialize in comprehensive TRD evaluation and treatment — including pharmacological management, ketamine-assisted therapy, functional medicine workup, and care coordination for patients who need TMS or other specialized interventions. We serve patients from Pocatello, Chubbuck, Blackfoot, American Falls, Twin Falls, and throughout the surrounding region.

Telehealth is available for initial consultation and ongoing medication management.

Why am I still depressed after taking antidepressants? The most likely reasons are: the medication(s) tried don't match your underlying neurobiology; there is an unaddressed physiological contributor (thyroid, inflammation, hormones, nutritional deficiency); the dose or duration of prior trials was inadequate; or you have a comorbid condition (ADHD, trauma, bipolar) that is perpetuating the depression.

What defines treatment-resistant depression clinically? Failure to achieve adequate response to at least two antidepressant medications of different classes at adequate doses for adequate durations (typically 6–8 weeks each).

Is there a cure for treatment-resistant depression? The word "cure" should be used cautiously, but many patients with TRD achieve full symptom remission and sustained wellness with appropriate treatment. The goal is remission — not just reduction — and it is achievable for the majority of patients who access the right level of care.

Are there non-drug treatments for TRD? Yes. TMS therapy, ketamine/esketamine, ECT, and specific psychotherapy approaches all have strong evidence bases for TRD. Functional medicine interventions that address underlying physiology are also meaningful.

1. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
2. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894–902.
3. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):26–31.
4. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any treatment decisions.

Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho | 208-904-4705 | www.rothfamilymed.com